CN109142749A - 一种心型脂肪酸结合蛋白检测试剂盒 - Google Patents

一种心型脂肪酸结合蛋白检测试剂盒 Download PDF

Info

Publication number
CN109142749A
CN109142749A CN201810910553.9A CN201810910553A CN109142749A CN 109142749 A CN109142749 A CN 109142749A CN 201810910553 A CN201810910553 A CN 201810910553A CN 109142749 A CN109142749 A CN 109142749A
Authority
CN
China
Prior art keywords
reagent
fatty acid
binding protein
acid binding
glycine buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810910553.9A
Other languages
English (en)
Inventor
黄信用
吕崇翔
曹春梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JINHUA KINGS BIOLOGICAL TECHNOLOGY Co Ltd
Original Assignee
JINHUA KINGS BIOLOGICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JINHUA KINGS BIOLOGICAL TECHNOLOGY Co Ltd filed Critical JINHUA KINGS BIOLOGICAL TECHNOLOGY Co Ltd
Priority to CN201810910553.9A priority Critical patent/CN109142749A/zh
Publication of CN109142749A publication Critical patent/CN109142749A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种心型脂肪酸结合蛋白检测试剂盒，包括试剂R1与试剂R2，所述R1试剂包括甘氨酸缓冲液100‑300mmol/L，牛血清白蛋白3‑8mmol/L，巯基乙醇30‑50mmol/L，二硫苏糖醇60‑80mmol/L，黄嘌呤氧化酶1.5‑3.7KU/L，草氨酸钠10‑20mmol/L，氯化钾8‑15mmol/L，所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球20‑35mg/L，甘氨酸缓冲液40‑60mmol/L，牛血清白蛋白2‑6mmol/L，乙二胺四乙酸22‑30mmol/L，甲基异噻唑啉酮15‑28mmol/L，磷酸二氢钾12‑16mmol/L；该心型脂肪酸结合蛋白检测试剂盒能够消除肠型脂肪酸结合蛋白的干扰，并具有反应效果好、检测稳定性能高的特点，大大的提高了使用者的使用检测精确性。

Description

一种心型脂肪酸结合蛋白检测试剂盒
技术领域
本发明涉及一种心型脂肪酸结合蛋白检测试剂盒。
背景技术
心型脂肪酸结合蛋白(hFABP)是心脏中富含的一种新型小胞质蛋白。它具有高度心脏特异性，但在心脏以外的组织中也有低浓度表达。心肌缺血性损伤出现后，hFABP可以早在胸痛发作后1-3小时在血液中被发现，6-8小时达到峰值而且血浆水平在24-30小时内恢复正常。心脏脂肪酸结合胞质蛋白由132个氨基酸组成，分子量为15kDa。心型脂肪酸结合蛋白(hFABP)基因位于染色体I上。它是心脏最丰富的蛋白质之一。hFABP结合两个脂肪酸分子并参与脂肪酰基辅酶A的运输，活跃于氧化过程，从而在线粒体中产生能量。目前，H-FABP的测定方法有酶联免疫法、放射免疫法与免疫层析等，但这些检测方法都存在一些缺陷，这些检测所存在的缺陷限制了它们的在临床诊断中的大规模应用，如检测过程中容易因溶液浓度与个体差异的情况造成检测干扰问题，抗干扰能力差，且试剂存放稳定性差，检测灵敏度不高，检测精确度与检测效果低下的缺点。
发明内容
本发明主要解决现有技术所存在的技术问题，从而提供一种能够有效增加检测稳定性与抗干扰能力，有效提高检测精确度与检测效果，提高了使用者大规模的进行检测应用的心型脂肪酸结合蛋白检测试剂盒。
为解决上述问题，本发明采用如下技术方案，包括试剂R1与试剂R2，所述R1试剂包括甘氨酸缓冲液100-300mmol/L，牛血清白蛋白3-8mmol/L，巯基乙醇30-50mmol/L，二硫苏糖醇60-80mmol/L，黄嘌呤氧化酶1.5-3.7KU/L，草氨酸钠10-20mmol/L，氯化钾8-15mmol/L；
所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球20-35mg/L，甘氨酸缓冲液40-60mmol/L，牛血清白蛋白2-6mmol/L，乙二胺四乙酸22-30mmol/L，甲基异噻唑啉酮15-28mmol/L，磷酸二氢钾12-16mmol/L。
作为优选，所述心型脂肪酸结合蛋白抗体的纳米微球的粒子直径为70-90nm。
作为优选，所述试剂R1与试剂R2的混合体积比为2:1，其中试剂R1中的甘氨酸缓冲液PH值在7.0-8.0，试剂R2中的甘氨酸缓冲液PH值在7.0-7.5。
作为优选，所述R1试剂包括甘氨酸缓冲液200mmol/L，牛血清白蛋白5mmol/L，巯基乙醇40mmol/L，二硫苏糖醇70mmol/L，黄嘌呤氧化酶2.8KU/L，草氨酸钠15mmol/L，氯化钾12mmol/L，所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球28mg/L，甘氨酸缓冲液50mmol/L，牛血清白蛋白4mmol/L，乙二胺四乙酸27mmol/L，甲基异噻唑啉酮22mmol/L，磷酸二氢钾14mmol/L。
本发明的有益效果是：该心型脂肪酸结合蛋白检测试剂盒能够有效增加检测稳定性与抗干扰能力，有效提高检测精确度与检测效果，提高了使用者大规模的进行检测应用。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明，但下述实施例仅仅为本发明的优选实施例，并非全部。基于实施方式中的实施例，本领域技术人员在没有做出创造性劳动的前提下所获得其它实施例，都属于本专利的保护范围。
一种心型脂肪酸结合蛋白检测试剂盒包括试剂R1与试剂R2，所述R1试剂包括甘氨酸缓冲液100-300mmol/L，牛血清白蛋白3-8mmol/L，巯基乙醇30-50mmol/L，二硫苏糖醇60-80mmol/L，黄嘌呤氧化酶1.5-3.7KU/L，草氨酸钠10-20mmol/L，氯化钾8-15mmol/L；所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球20-35mg/L，甘氨酸缓冲液40-60mmol/L，牛血清白蛋白2-6mmol/L，乙二胺四乙酸22-30mmol/L，甲基异噻唑啉酮15-28mmol/L，磷酸二氢钾12-16mmol/L。
所述心型脂肪酸结合蛋白抗体的纳米微球的粒子直径为70-90nm。
所述试剂R1与试剂R2的混合体积比为2:1，其中试剂R1中的甘氨酸缓冲液PH值在7.0-8.0，试剂R2中的甘氨酸缓冲液PH值在7.0-7.5。
作为优选，所述R1试剂包括甘氨酸缓冲液200mmol/L，牛血清白蛋白5mmol/L，巯基乙醇40mmol/L，二硫苏糖醇70mmol/L，黄嘌呤氧化酶2.8KU/L，草氨酸钠15mmol/L，氯化钾12mmol/L，所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球28mg/L，甘氨酸缓冲液50mmol/L，牛血清白蛋白4mmol/L，乙二胺四乙酸27mmol/L，甲基异噻唑啉酮22mmol/L，磷酸二氢钾14mmol/L。
本发明的有益效果是：该心型脂肪酸结合蛋白检测试剂盒能够有效增加检测稳定性与抗干扰能力，有效提高检测精确度与检测效果，提高了使用者大规模的进行检测应用。
以在所述，仅为本发明的具体实施方式，但本发明的保护范围并不局限于此，任何不经过创造性劳动想到的变化或替换，都应涵盖在本发明保护范围内。

Claims (4)

1.一种心型脂肪酸结合蛋白检测试剂盒，其特征在于：包括试剂R1与试剂R2，所述R1试剂包括甘氨酸缓冲液100-300mmol/L，牛血清白蛋白3-8mmol/L，巯基乙醇30-50mmol/L，二硫苏糖醇60-80mmol/L，黄嘌呤氧化酶1.5-3.7KU/L，草氨酸钠10-20mmol/L，氯化钾8-15mmol/L；
所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球20-35mg/L，甘氨酸缓冲液40-60mmol/L，牛血清白蛋白2-6mmol/L，乙二胺四乙酸22-30mmol/L，甲基异噻唑啉酮15-28mmol/L，磷酸二氢钾12-16mmol/L。
2.根据权利要求1所述的一种心型脂肪酸结合蛋白检测试剂盒，其特征在于：所述心型脂肪酸结合蛋白抗体的纳米微球的粒子直径为70-90nm。
3.根据权利要求1所述的一种心型脂肪酸结合蛋白检测试剂盒，其特征在于：所述试剂R1与试剂R2的混合体积比为2:1，其中试剂R1中的甘氨酸缓冲液PH值在7.0-8.0，试剂R2中的甘氨酸缓冲液PH值在7.0-7.5。
4.根据权利要求1所述的一种心型脂肪酸结合蛋白检测试剂盒，其特征在于：所述R1试剂包括甘氨酸缓冲液200mmol/L，牛血清白蛋白5mmol/L，巯基乙醇40mmol/L，二硫苏糖醇70mmol/L，黄嘌呤氧化酶2.8KU/L，草氨酸钠15mmol/L，氯化钾12mmol/L，所述试剂R2包括包被心型脂肪酸结合蛋白抗体的纳米微球28mg/L，甘氨酸缓冲液50mmol/L，牛血清白蛋白4mmol/L，乙二胺四乙酸27mmol/L，甲基异噻唑啉酮22mmol/L，磷酸二氢钾14mmol/L。
CN201810910553.9A 2018-08-11 2018-08-11 一种心型脂肪酸结合蛋白检测试剂盒 Pending CN109142749A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810910553.9A CN109142749A (zh) 2018-08-11 2018-08-11 一种心型脂肪酸结合蛋白检测试剂盒

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810910553.9A CN109142749A (zh) 2018-08-11 2018-08-11 一种心型脂肪酸结合蛋白检测试剂盒

Publications (1)

Publication Number Publication Date
CN109142749A true CN109142749A (zh) 2019-01-04

Family

ID=64792811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810910553.9A Pending CN109142749A (zh) 2018-08-11 2018-08-11 一种心型脂肪酸结合蛋白检测试剂盒

Country Status (1)

Country Link
CN (1) CN109142749A (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102628864A (zh) * 2011-12-30 2012-08-08 北京九强生物技术股份有限公司 胶乳增强免疫比浊法测定血清或尿液中心脏型脂肪酸结合蛋白的试剂盒
CN102788880A (zh) * 2012-08-16 2012-11-21 北京恩济和生物科技有限公司 一种心型脂肪酸结合蛋白检测试剂盒及其制备方法
CN103123319A (zh) * 2012-12-20 2013-05-29 武汉生之源生物科技有限公司 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法
CN104215772A (zh) * 2014-08-14 2014-12-17 上海睿康生物科技有限公司 心脏型脂肪酸结合蛋白检测试剂盒及其制备方法
CN105929176A (zh) * 2016-05-26 2016-09-07 安徽伊普诺康生物技术股份有限公司 一种测定心型脂肪酸结合蛋白的试剂盒及其制备方法
CN106324251A (zh) * 2016-08-08 2017-01-11 上海睿康生物科技有限公司 小片段BMG抗体的制备方法及β2‑微球蛋白检测试剂盒
CN106443014A (zh) * 2016-09-20 2017-02-22 上海科华生物工程股份有限公司 缺血修饰白蛋白的检测试剂盒及其制备方法
CN106771148A (zh) * 2016-12-28 2017-05-31 广州华弘生物科技有限公司 一种免疫球蛋白m检测试剂盒及检测方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102628864A (zh) * 2011-12-30 2012-08-08 北京九强生物技术股份有限公司 胶乳增强免疫比浊法测定血清或尿液中心脏型脂肪酸结合蛋白的试剂盒
CN102788880A (zh) * 2012-08-16 2012-11-21 北京恩济和生物科技有限公司 一种心型脂肪酸结合蛋白检测试剂盒及其制备方法
CN103123319A (zh) * 2012-12-20 2013-05-29 武汉生之源生物科技有限公司 心型脂肪酸结合蛋白含量检测试剂盒及其制备方法
CN104215772A (zh) * 2014-08-14 2014-12-17 上海睿康生物科技有限公司 心脏型脂肪酸结合蛋白检测试剂盒及其制备方法
CN105929176A (zh) * 2016-05-26 2016-09-07 安徽伊普诺康生物技术股份有限公司 一种测定心型脂肪酸结合蛋白的试剂盒及其制备方法
CN106324251A (zh) * 2016-08-08 2017-01-11 上海睿康生物科技有限公司 小片段BMG抗体的制备方法及β2‑微球蛋白检测试剂盒
CN106443014A (zh) * 2016-09-20 2017-02-22 上海科华生物工程股份有限公司 缺血修饰白蛋白的检测试剂盒及其制备方法
CN106771148A (zh) * 2016-12-28 2017-05-31 广州华弘生物科技有限公司 一种免疫球蛋白m检测试剂盒及检测方法

Similar Documents

Publication Publication Date Title
Lang Creatine kinase isoenzymes: pathophysiology and clinical application
Mery et al. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes.
Kury et al. Regulation of membrane flexibility in human erythrocytes
US4578361A (en) Creatinine antibody
Nissim et al. Effect of glutamine on heat‐shock‐induced mRNA and stress proteins
Rodemann et al. Abnormal collagen metabolism in cultured skin fibroblasts from patients with Duchenne muscular dystrophy.
Krumwiede Studies on a lipoproteinase of group A streptococci
EP0084655B1 (de) Verfahren und Reagenz zur Bestimmung von Creatinin
DE3872575T2 (de) Ckmb-bestimmung, monoclonale antikoerper zur verwendung darin und hybrid-zellinien.
CN109142749A (zh) 一种心型脂肪酸结合蛋白检测试剂盒
Oguchi Glyceraldehyde-3-phosphate dehydrogenase from human erythrocytes
Karonen et al. Evaluation of the double antibody-solid phase radioimmunoassay technique in plasma LH and FSH and urinary LH measurements
Leach Some observations on the state of sialic acid in human saliva
Sur et al. Starch-gel electrophoresis of prostatic acid phosphatase
Donahue et al. Correlation of muscle activity with glycogen metabolism in muscle of Ascaris suum
Closs et al. [9] Identification of carrier systems in plasma membranes of mammalian cells involved in transport of l-arginine
Dunnick et al. Effect of detergents and sodium fluoride on the enzyme activities of the rat liver plasma membrane
Nicolson et al. Quantitative determination of plant agglutinin membrane sites on mammalian spermatozoa
DE2908053C2 (de) Verfahren und Reagenz zur Bestimmung der Creatinkinase MB
McIlwain The Nutrition of Streptococcus hæmolyticus. Growth in a Chemically Defined Mixture; Need for Vitamin B6
Wood The purification of enolase from cerebral tissue
Lahav et al. Calmodulin inhibitors and 8-(N, N-diethylamino)-octyl-3, 4, 5-trimethoxybenzoate do not prevent the inhibitory effect of prostaglandin F2α on cyclic AMP production in isolated rat corpora lutea
Abul-Fadl A Note on the Determination of β-Glucuronidase Activity in Urine
Gässler et al. A high performance liquid chromatography method for the determination of glycosaminoglycans in human blood
Meek et al. The biologic activity of insulin A and B chains as determined by the rat diaphragm and epididymal fat pad

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190104